Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial

OBJECTIVE: Type 2 diabetes is a leading cause of kidney failure, but few outcome trials proactively enrolled individuals with chronic kidney disease (CKD). We performed secondary analyses of cardiovascular (CV) and kidney outcomes across baseline estimated glomerular filtration rate (eGFR) categorie...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Diabetes Care
Glavni autori: Perkovic, Vlado, Toto, Robert, Cooper, Mark E., Mann, Johannes F.E., Rosenstock, Julio, McGuire, Darren K., Kahn, Steven E., Marx, Nikolaus, Alexander, John H., Zinman, Bernard, Pfarr, Egon, Schnaidt, Sven, Meinicke, Thomas, von Eynatten, Maximillian, George, Jyothis T., Johansen, Odd Erik, Wanner, Christoph
Format: Artigo
Jezik:Inglês
Izdano: American Diabetes Association 2020
Teme:
Emerging Therapies: Drugs and Regimens
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7372065/
https://ncbi.nlm.nih.gov/pubmed/32444457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc20-0279
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items